The FDA has accepted for Priority Review the BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis.

Social media users claimed the US Food and Drug Administration (FDA) recently disclosed that people vaccinated against ...

The adenoviridae family is divided into two genera: aviadenovirus, which causes disease in birds, and mastadenovirus, which infects a wide range of species, including humans. Human adenoviruses ...

Bharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and manufacturing, ...

Bharat Biotech aims to democratize gene therapies, traditionally considered prohibitively expensive and available primarily ...

Bharat Biotech invests $75 million in India's first Cell & Gene Therapy facility, focusing on advanced therapies and ...

GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with a ...

Hyderabad: Bharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and ...

PRGN-2012 is an adenovirus vector-based gene therapy expected to induce immune responses against HPV 6 or 11 infected cells. Findings showed among those treated at the recommended PRGN-2012 dose ...

No writing assistance was utilized in the production of this manuscript. Future Oncol. 2009;5(3):339-357. © 2009 Future Medicine Ltd. Cite this: Oncolytic Adenoviral ...

Our Bureau, Bengaluru Thursday, March 20, 2025, 17:40 Hrs [IST] ...